Caitong International Asset Management’s Unicycive Therapeutics UNCY Stock Holding History

Caitong International Asset Management’s Portfolio UNCY Stock Details UNCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33	Buy	+5	New	+$33	﹤0.01%	2043

Other funds holding UNCY

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caitong International Asset Management's UNCY Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Unicycive Therapeutics (UNCY) in Q1 2026: 5 shares worth $33. The stake represents ﹤0.01% of the portfolio and ranks #2043 among its holdings.

51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

Caitong International Asset Management held 5 shares of Unicycive Therapeutics worth $33 as of Q1 2026.
Unicycive Therapeutics was a new Caitong International Asset Management position in Q1 2026.
Unicycive Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2043 holding.
51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.